Jerman Michael Allen 4

What Happened
Michael Allen, a director of Inhibitor Therapeutics, was awarded 50,000 shares of restricted common stock on May 4, 2026. The Form 4 reports the award as an acquisition (transaction code A) at $0.00 per share (total cash consideration $0), issued as compensation under the issuer's 2025 Equity Incentive Plan.

Key Details

• Transaction date: 2026-05-04 (Grant / Award, code A)
• Price: $0.00 per share; Total cash paid: $0
• Shares awarded: 50,000 restricted common shares (see footnote F1: issued as compensation under the 2025 Equity Incentive Plan)
• Shares owned after transaction: not specified in the excerpt provided
• Filing date: Form 4 filed 2026-06-24 — this is later than the typical 2-business-day reporting window for insider transactions

Context
Restricted stock awards are compensation and are often subject to vesting and other transfer restrictions; they do not represent an open-market purchase or sale and therefore are not a direct market-timing signal. The footnote clarifies these shares were issued under the company's equity plan as part of compensation to the director.